Belite Bio (BLTE) Free Cash Flow (2024 - 2025)
Belite Bio (BLTE) recorded quarterly Free Cash Flow of -$10.4 million in Q4 2025, down 114.88% quarter-over-quarter from -$4.8 million in Q4 2024, and down 114.88% on a YoY basis from $69.8 million in Q4 2024.
Belite Bio (BLTE) Free Cash Flow (2024 - 2025) Analysis & Trends
Belite Bio's Free Cash Flow history runs 2 years deep, the most recent figure standing at -$10.4 million for Q4 2025.
- In Q4 2025, Free Cash Flow fell 114.88% year-over-year to -$10.4 million; the TTM figure through Mar 2026 stood at -$10.4 million (down 114.88% YoY), while the FY2025 annual figure was -$37.1 million, down 26.27% from the prior year.
- Free Cash Flow was -$10.4 million for Q4 2025 at Belite Bio, down from -$4.8 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$4.8 million in Q4 2024 to a low of -$10.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 848.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -10.39 Mn |
| Dec 31, 2025 | -10.39 Mn |
| Dec 31, 2024 | -4.83 Mn |
| Dec 31, 2024 | -4.83 Mn |